When asked about future PPX in hemophilia patients without inhibitors, the majority of the experts (88.9%) agreed that the new class of FVIII replacement therapy, namely efanesoctocog alfa (BIVV001), shows promise to become a mainstream option because it has the potential for more optimal, extended protection against all bleeding types in patients with severe hemophilia A, as compared with other hemostasis rebalancing therapies and bispecific monoclonal antibodies such as emicizumab. This evidence concerns the gene F8 and hemophilia A.